Boston Scientific's second quarter was shaped by healthy growth in its Interventional Cardiology, Endoscopy, and Neuromodulation businesses, which counterbalanced notable slowdowns in Electrophysiology and the WATCHMAN left atrial appendage closure device. CEO Michael Mahoney acknowledged the unexpected pace of U.S. market changes for WATCHMAN and competitive pressures in Electrophysiology, both of which led to a more cautious outlook. Management described the environment as “dynamic” and outlined how clinical evidence and referral patterns directly affected WATCHMAN volumes. The company also cited integration progress with recent acquisitions as a positive contributor to segment performance.
Is now the time to buy BSX? Find out in our full research report (it’s free for active Edge members).
Boston Scientific (BSX) Q2 CY2026 Highlights:
- Revenue: $5.44 billion vs analyst estimates of $5.36 billion (7.5% year-on-year growth, 1.5% beat)
- Adjusted EPS: $0.86 vs analyst estimates of $0.83 (3.8% beat)
- Revenue Guidance for Q3 CY2026 is $5.27 billion at the midpoint, below analyst estimates of $5.39 billion
- Management lowered its full-year Adjusted EPS guidance to $3.30 at the midpoint, a 2.2% decrease
- Operating Margin: 21.6%, up from 16.2% in the same quarter last year
- Market Capitalization: $71.14 billion
While we enjoy listening to the management’s commentary, our favorite part of earnings calls is the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.
Our Top 5 Analyst Questions From Boston Scientific’s Q2 Earnings Call
- Robert Marcus (JPMorgan): Asked if the guidance reset was conservative or based on current trends. CEO Michael Mahoney clarified the changes are driven by persistent declines in WATCHMAN and Electrophysiology, with limited near-term improvement assumed in the outlook.
- Larry Biegelsen (Wells Fargo): Inquired about expected WATCHMAN performance and new competitive threats. Mahoney said U.S. WATCHMAN is expected to remain flat or decline until market dynamics change, acknowledging likely share erosion with new entrants in 2027.
- Joanne Wuensch (Citibank): Sought clarity on 2027-2028 growth drivers. Mahoney described seven upcoming product launches and adjacencies, including IVL and hypertension solutions, as key to restoring high growth beyond next year.
- Frederick Wise (Stifel): Asked about restructuring impacts and reinvestment plans. CFO Jonathan Monson explained cost savings would be phased, with early benefits in SG&A and reinvestment focused on growth platforms.
- Michael Polark (Wolfe Research): Questioned steps to address shifting referral patterns in WATCHMAN. Chief Medical Officer Dr. Ken Stein emphasized education, expanded indications, and ongoing clinical trials to support future growth.
Catalysts in Upcoming Quarters
In the coming quarters, the StockStory team will be monitoring (1) the pace of recovery and mitigation strategies for U.S. WATCHMAN and Electrophysiology, (2) progress in integrating the Penumbra acquisition and its cardiovascular portfolio, and (3) execution of restructuring initiatives aimed at cost savings. The timing and success of key product launches and regulatory milestones will also be critical markers for improved performance.
Boston Scientific currently trades at $49.13, up from $46.06 just before the earnings. Is the company at an inflection point that warrants a buy or sell? See for yourself in our full research report (it’s free).
High-Quality Stocks for All Market Conditions
ONE MORE THING: Top 5 Growth Stocks. The biggest stock winners almost always had one thing in common before they ran. Revenue growing like crazy. Meta. CrowdStrike. Broadcom. Our AI flagged all three. They returned 315%, 314%, and 455%, respectively.
Find out which 5 stocks it’s flagging this month — FREE. Get Our Top 5 Growth Stocks for Free HERE.
Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+214% between June 2020 and June 2025). Find your next big winner with StockStory today.
